Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.
Type:
Application
Filed:
September 18, 2013
Publication date:
February 13, 2014
Applicants:
University of Rochester, The Los Angles Biomedical Research Institute at Harbor-UCLA Medical Center, University of Guelph
Inventors:
Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J Waring, Frans Walther, Larry M. Gordon
Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
Type:
Application
Filed:
January 5, 2007
Publication date:
December 3, 2009
Applicant:
Los Angles Biomedical Research Institute at Harbor Ucla Medical Center
Inventors:
John Edwards, Scott Filler, Ashraf Ibrahim, Yue Fu, Brad Spellberg, Michael Yeaman